<DOC>
	<DOCNO>NCT02159066</DOCNO>
	<brief_summary>The primary purpose study assess anti-tumor activity LGX818/MEK162 combination target agent progression LGX818/MEK162 combination therapy , well safety tolerability novel triple combination .</brief_summary>
	<brief_title>LGX818 MEK162 Combination With Third Agent ( BKM120 , LEE011 , BGJ398 INC280 ) Advanced BRAF Melanoma</brief_title>
	<detailed_description>This study consist two part : Part I/Run-In , patient naïve selective BRAF MEK inhibitor treat LGX818/MEK162 combination disease progression ( define per RECIST v1.1 ) . Based genetic analysis tumor biopsy obtain time , patient enter Part II study tailor combination treatment one four arm LGX818/MEK162 + either BKM120 , BGJ398 , INC280 LEE011 Patients BRAF mutant melanoma treat LGX818/MEK162 combination study enrol directly Part II CLGX818X2109 relapse . Dose-escalations combination arm MTD establish base recommendation Bayesian logistic regression model guide escalation overdose control criterion</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<criteria>INCLUSION CRITERIA : Age ≥ 18 year Histologically confirm diagnosis unresectable stage III metastatic melanoma ( stage IIIC IV per American Joint Committee Cancer [ AJCC ] ) Documented evidence BRAF V600 mutation . Newly obtain tumor biopsy baseline , patient agree mandatory biopsy time progression , medically contraindicate . Evidence measurable disease , determine RECIST v1.1 . INCLUSION CRITERIA triple combination : Progressive disease follow prior treatment LGX818/MEK162 combination . PRINCIPAL EXCLUSION CRITERIA Symptomatic untreated leptomeningeal disease . Symptomatic brain metastasis . Patients previously treat untreated brain metastasis asymptomatic absence corticosteroid therapy stable dose steroid four week allow enroll . Brain metastasis must stable least 4 week verification imaging ( e.g . brain MRI complete screen demonstrate current evidence progressive brain metastasis ) . Patients permit receive enzyme induce antiepileptic drug . Patients develop brain metastasis Part I study may continue Part II upon discussion Novartis Medical Monitor . The brain metastasis must either asymptomatic treat stable least 4 week stable taper dose steroid least 2 week . Patients brain metastasis eligible combination LEE011 . Known acute chronic pancreatitis . History current evidence retinal vein occlusion ( RVO ) current risk factor RVO ( e.g . uncontrolled glaucoma ocular hypertension , history hyperviscosity hypercoagulability syndrome ) ; Clinically significant cardiac disease include follow : CHF require treatment ( NYH grade ≥ 2 ) , LVEF &lt; 50 % determine MUGA scan ECHO History presence clinically significant ventricular arrhythmia atrial fibrillation Clinically significant rest bradycardia Unstable angina pectoris ≤ 3 month prior start study drug Acute Myocardial Infarction ( AMI ) ≤ 3 month prior start study drug , QTcF &gt; 480 msec . Patients follow laboratory value Screening/baseline : Absolute neutrophil count ( ANC ) &lt; 1,500/mm3 [ 1.5 x 109/L ] Platelets &lt; 100,000/mm3 [ 100 x 109/L ] Hemoglobin &lt; 9.0 g/dL Serum creatinine &gt; 1.5 x ULN calculate directly measure CrCl &lt; 50 % LLN ( low limit normal ) Serum total bilirubin &gt; 1.5 x ULN AST/SGOT ALT/SGPT &gt; 2.5 x ULN , &gt; 5 x ULN liver metastases present Additional exclusion criterion triple combination : LGX818/MEK162/BKM120 : Patients fast glucose &gt; 120 mg/dL 6.7 mmol/L , HbA1c &gt; 8 % . Patient follow mood disorder judge Investigator Psychiatrist : Patient score ≥ 12 PHQ9 questionnaire Patient ≥ CTCAE grade 3 anxiety LGX818/MEK162/BGJ398 : History and/or current evidence significant ectopic mineralization/ calcification exception calcify lymph node asymptomatic vascular calcification . Current evidence corneal disorder/ keratopathy incl . limited bullous/ band keratopathy , corneal abrasion , inflammation/ulceration , keratoconjunctivits etc. , confirm ophthalmologic examination LGX818/MEK162/LEE011 : Patients uncontrolled hypertension ( please refer WHOISHguidelines ) exclude study . QTcF &gt; 450 m male &gt; 470 m female Congenital long QT syndrome family history unexpected sudden cardiac death and/or hypokalemia CTCAE Grade ≥ 3 magnesium level clinically relevant low limit study entry Current evidence brain metastasis brain metastasis detect mandatory CT/MRI screen PT/INR aPTT &gt; 1.5xULN Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Melanoma</keyword>
</DOC>